Soybean oil–based intravenous fat emulsions have long been used as the primary product for delivery of lipid-based calories in parenteral nutrition formulations in the United States. Proinflammatory properties of these products may be related with poor clinical outcomes and have led investigators to develop newer generations of intravenous fat emulsions. These alternative formulations are derivatives of medium-chain triglycerides, olive oil, and fish oil in hopes to reduce the inflammatory response and potentially produce a clinically beneficial anti-inflammatory response. Although surrogate markers support this reduction in inflammatory response, clinical data and outcomes are still limited but potentially promising in the literature. This product review provides a general overview of the alternative-generation intravenous fat emulsion products and the literature supporting the potential transition to such products.
WaitzbergDLTorrinhasRSJacinthoTM. New parenteral lipid emulsions for clinical use. JPEN J Parenter Enteral Nutr. 2006;30:351-367.
2.
CalderPC. Hot topics in parenteral nutrition: rationale for using new lipid emulsions in parenteral nutrition and a review of the trials performed in adults. Proc Nutr Soc. 2009;68:252-260.
3.
GrimbleR. Fatty acid profile of modern lipid emulsions: scientific considerations for creating the ideal composition. Clin Nutr Supp. 2005;1:9-15.
4.
KumpfVJ. Parenteral nutrition-associated liver disease in adults and pediatric patients. Nutr Clin Pract. 2006;21:279-290.
5.
TashiroTYamamoriHTakagiKHayashiNFurukawaKNakajimaN. n-3 versus n-6 polyunsaturated fatty acids in critical illness. Nutrition. 1998;14(6):551-553.
6.
SchmitzGEckerJ. The opposing effects of n-3 and n-6 fatty acids. Prog Lipid Res. 2008;47:147-155.
7.
SimopoulosAP. The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother. 2002;56:365-379.
8.
DasilvaGPazosMGarcia-EgidoE. Healthy effect of different proportions of marine ω-3 PUFAs EPA and DHA supplementation in Wistar rats: Lipidomic biomarkers of oxidative stress and inflammation. J Nutr Biochem. 2015;26:1385-1392.
9.
SerhanCN. Controlling the resolution of acute inflammation: a new genus of dual anti-inflammatory and proresolving mediators. J Periodontol. 2008;79(8)(suppl):1520-1526.
SerhanCNYacoubianSYangR. Anti-inflammatory and proresolving lipid mediators. Annu Rev Pathol. 2008;3:279-312.
12.
WuGHZanioloOSchusterHSchlotzerEPradelliL. Structured triglycerides versus physical mixtures of medium- and long-chain triglycerides for parenteral nutrition in surgical or critically ill adult patients: systematic review and meta-analysis [published online January21, 2016]. Clin Nutr.
13.
VanekVWSeidnerDLAllenP. ASPEN position paper: clinical role for alternative intravenous fat emulsions. Nutr Clin Pract. 2012;27(2):150-192.
14.
Structolipid 20% emulsion for infusion [package insert]. Uppsala, Sweden: Fresenius Kabi AB; 2008.
15.
SMOFlipid 200 mg/mL emulsion for infusion [package insert]. Cheshire, UK: Fresenius Kabi Limited; 2015.
16.
Lipofundin MCT/LCT 10% emulsion for injection [package insert]. Melsungen, Germany: B. Braun Melsungen AG; 2014.
17.
Lipovenoes 10% and 20% [package insert]. Graz, Austria: Fresenius Kabi Austria GmbH.
18.
KoletzkoBGouletOHuntJKrohnKShamirR. Guidelines on paediatric parenteral nutrition of the European Society of Paediatric Gastroenterology, Hepatology and Nutrition (ESPGHAN) and the European Society for Clinical Nutrition and Metabolism (ESPEN), supported by the European Society of Paediatric Research (ESPR). J Pediatr Gastroenterol Nutr. 2005;41:S1-S4.
Clinolipid (lipid injectable emulsion) for intravenous use [package insert]. Deerfield, IL: Baxter Healthcare Corp; 2013.
21.
Omegaven (emulsion for infusion) [package insert]. Bad Homburg, Germany: Fresenius Kabi; 2012.
22.
De MeijerVELeHDMeiselJAGuraKMPuderM. Parenteral fish oil as monotherapy prevents essential fatty acid deficiency in parenteral nutrition dependent patients. J Pediatr Gastroenterol Nutr. 2010;50(2):212-218.
23.
LeHDde MeijerVERobinsonEM. Parenteral fish-oil-based lipid emulsion improves fatty acid profiles and lipids in parenteral nutrition-dependent children. Am J Clin Nutr. 2011;94(3):749-758.
24.
Lipidem 200 mg/mL emulsion for infusion [package insert]. Melsungen, Germany: B. Braun Melsungen AG; 2014.
25.
Kabiven (aminoacids, electrolytes, dextrose and lipid injectable emulsion), for intravenous use [package insert]. Uppsala, Sweden: Fresenius Kabi; 2014.
26.
Perikabiven (aminoacids, electrolytes, dextrose and lipid injectable emulsion), for intravenous use [package insert]. Uppsala, Sweden: Fresenius Kabi; 2014.
27.
HardyFPuzovicM. Formulation, stability, and administration of parenteral nutrition with new lipid emulsions. Nutr Clin Pract. 2009;24(5):616-625.
28.
DriscollDFGiampietroKWichelhausDP. Physicochemical stability assessments of lipid emulsions of varying oil composition. Clin Nutr. 2001;20:151-157.
29.
DriscollDNehneJPeterssHRolfFBistrianBNiemannW. The influence of medium-chain triglycerides on the stability of all-in-one formulations. Int J Pharm. 2002;240:1-10.
30.
TaylorBMcClaveSMartindaleR; Society of Critical Care Medicine, American Society for Parenteral and Enteral Nutrition. Guidelines for the provision and assessment of nutrition support therapy in the adult critically ill patient: Society of Critical Care Medicine (SCCM) and American Society for Parenteral and Enteral Nutrition (ASPEN). Crit Care Med. 2016;44(2):390-438.
31.
ManzanaresWDhaliwalRJurewitschBStapletonRDJeejeebhoyKNHeylandDK. Parenteral fish oil lipid emulsion in the critically ill: a systematic review and meta-analysis. JPEN J Parenter Enteral Nutr. 2014;38(1):20-28.
32.
EdmundsCEBrodyRAParrottJSStankorbSMHeylandDK. The effects of different IV fat emulsions on clinical outcomes in the critically ill. Crit Care Med. 2014;42:1168-1177.
33.
ManzanaresWLangloisPLDhaliwalRLemieuxMHeylandD. Intravenous fish oil lipid emulsion in critically ill patients: an updated systemic review and meta-analysis. Crit Care. 2015;19:167-182.
34.
GuraKMParsonsSKBechardLJ. Use of a fish oil-based lipid emulsion to treat essential fatty acid deficiency in a soy allergic patient receiving parenteral nutrition. Clin Nutr. 2005;24(5):839-847.
35.
ParkHWLeeNMKimJHKimKSKimSN. Parenteral fish oil-containing lipid emulsions may reverse parenteral nutrition-associated cholestasis in neonates: a systemic review and meta-analysis. J Nutr. 2015;145;277-283.
36.
PremkumarMHCarterBAHawthorneKMKingKAbramsSA. Fish oil-based lipid emulsions in the treatment of parenteral-nutrition associated liver disease: an ongoing positive experience. Adv Nutr. 2014;5:65-70.
37.
NandivadaPChangMIPotemkinAK. The natural history of cirrhosis form parenteral nutrition-associated liver disease after resolution of cholestasis with parenteral fish oil therapy. Ann Surg. 2015;26:172-179.
Nutriflex Omega plus emulsion for infusion [package insert]. Melsungen, Germany: B. Braun Melsungen AG; 2015.
53.
Nutriflex Omega special emulsion for infusion [package insert]. Melsungen, Germany: B. Braun Melsungen AG; 2015.
54.
SMOFKabiven emulsion for infusion [package insert]. Cheshire, UK: Fresenius Kabi Limited; 2016.
55.
SMOFKabiven Electrolyte Free emulsion for infusion [package insert]. Cheshire, UK: Fresenius Kabi Limited; 2016.
56.
SMOFKabiven Peripheral, emulsion for infusion [package insert]. Cheshire, UK: Fresenius Kabi Limited; 2015.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
